178 related articles for article (PubMed ID: 15829321)
1. Detection of autoantibodies to livin and survivin in Sera from lung cancer patients.
Yagihashi A; Asanuma K; Kobayashi D; Tsuji N; Shijubo Y; Abe S; Hirohashi Y; Torigoe T; Sato N; Watanabe N
Lung Cancer; 2005 May; 48(2):217-21. PubMed ID: 15829321
[TBL] [Abstract][Full Text] [Related]
2. Detection of autoantibodies to survivin and livin in sera from patients with breast cancer.
Yagihashi A; Ohmura T; Asanuma K; Kobayashi D; Tsuji N; Torigoe T; Sato N; Hirata K; Watanabe N
Clin Chim Acta; 2005 Dec; 362(1-2):125-30. PubMed ID: 16026775
[TBL] [Abstract][Full Text] [Related]
3. Expression of survivin mRNA and livin mRNA in non-small-cell lung cancer.
Tanabe H; Yagihashi A; Tsuji N; Shijubo Y; Abe S; Watanabe N
Lung Cancer; 2004 Dec; 46(3):299-304. PubMed ID: 15541814
[TBL] [Abstract][Full Text] [Related]
4. Antibody responses to survivin and their clinical significance in patients with head and neck cancer.
Eto M; Kodama S; Uemura N; Suzuki M
Head Neck; 2007 Dec; 29(12):1128-35. PubMed ID: 17636541
[TBL] [Abstract][Full Text] [Related]
5. [Immunologic tests: Anti-Survivin and anti-Livin antibodies].
Yagihashi A
Nihon Rinsho; 2005 Jul; 63 Suppl 7():637-9. PubMed ID: 16111355
[No Abstract] [Full Text] [Related]
6. Anti-survivin antibody responses in lung cancer.
Karanikas V; Khalil S; Kerenidi T; Gourgoulianis KI; Germenis AE
Cancer Lett; 2009 Sep; 282(2):159-66. PubMed ID: 19380192
[TBL] [Abstract][Full Text] [Related]
7. [Anti-survivin and anti-livin antibodies].
Yagihashi A
Nihon Rinsho; 2010 Jun; 68 Suppl 6():708-10. PubMed ID: 20942170
[No Abstract] [Full Text] [Related]
8. Expression of livin in renal cell carcinoma and detection of anti-livin autoantibody in patients.
Kitamura H; Honma I; Torigoe T; Hariu H; Asanuma H; Hirohashi Y; Sato E; Sato N; Tsukamoto T
Urology; 2007 Jul; 70(1):38-42. PubMed ID: 17656204
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies to survivin in patients with chronic hepatitis and hepatocellular carcinoma.
Yagihashi A; Asanuma K; Kobayashi D; Tsuji N; Torigoe T; Sato N; Watanabe N
Autoimmunity; 2005 Sep; 38(6):445-8. PubMed ID: 16278150
[TBL] [Abstract][Full Text] [Related]
10. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients.
Rohayem J; Diestelkoetter P; Weigle B; Oehmichen A; Schmitz M; Mehlhorn J; Conrad K; Rieber EP
Cancer Res; 2000 Apr; 60(7):1815-7. PubMed ID: 10766164
[TBL] [Abstract][Full Text] [Related]
11. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection.
Megliorino R; Shi FD; Peng XX; Wang X; Chan EK; Tan EM; Zhang JY
Cancer Detect Prev; 2005; 29(3):241-8. PubMed ID: 15896923
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of Survivin and Livin in nasopharyngeal carcinoma.
Xiang Y; Yao H; Wang S; Hong M; He J; Cao S; Min H; Song E; Guo X
Laryngoscope; 2006 Jan; 116(1):126-30. PubMed ID: 16481824
[TBL] [Abstract][Full Text] [Related]
13. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer.
Hariu H; Hirohashi Y; Torigoe T; Asanuma H; Hariu M; Tamura Y; Aketa K; Nabeta C; Nakanishi K; Kamiguchi K; Mano Y; Kitamura H; Kobayashi J; Tsukahara T; Shijubo N; Sato N
Clin Cancer Res; 2005 Feb; 11(3):1000-9. PubMed ID: 15709165
[TBL] [Abstract][Full Text] [Related]
14. The anti-apoptotic livin gene is an important determinant for the apoptotic resistance of non-small cell lung cancer cells.
Crnković-Mertens I; Muley T; Meister M; Hartenstein B; Semzow J; Butz K; Hoppe-Seyler F
Lung Cancer; 2006 Nov; 54(2):135-42. PubMed ID: 16965834
[TBL] [Abstract][Full Text] [Related]
15. Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: implications for specific immunotherapy.
Kitamura H; Torigoe T; Honma I; Asanuma H; Nakazawa E; Shimozawa K; Hirohashi Y; Sato E; Sato N; Tsukamoto T
Urology; 2006 May; 67(5):955-9. PubMed ID: 16635519
[TBL] [Abstract][Full Text] [Related]
16. A highly sensitive particle agglutination assay for the detection of P53 autoantibodies in patients with lung cancer.
Agaylan A; Binder D; Sauer M; Neuweiler H; Meyer O; Kiesewetter H; Salama A
Cancer; 2007 Dec; 110(11):2502-6. PubMed ID: 17932907
[TBL] [Abstract][Full Text] [Related]
17. Autoantibodies against the Hel-N1 RNA-binding protein among patients with lung carcinoma: an association with type I anti-neuronal nuclear antibodies.
Dropcho EJ; King PH
Ann Neurol; 1994 Aug; 36(2):200-5. PubMed ID: 8053656
[TBL] [Abstract][Full Text] [Related]
18. A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2.
Mainou-Fowler T; Overman LM; Dignum H; Wood K; Crosier S; Angus B; Proctor SJ; Anderson JJ
Int J Oncol; 2008 Jan; 32(1):59-68. PubMed ID: 18097543
[TBL] [Abstract][Full Text] [Related]
19. Correlation between anti-survivin antibody and survivin mRNA expression in head and neck cancer patients.
Uemura N; Kodama S; Nomi N; Okamoto T; Suzuki M
Acta Otolaryngol; 2010 Aug; 130(8):959-65. PubMed ID: 20100132
[TBL] [Abstract][Full Text] [Related]
20. Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy.
Ichiki Y; Hanagiri T; Takenoyama M; Baba T; Fukuyama T; Nagata Y; Mizukami M; So T; Sugaya M; Yasuda M; So T; Sugio K; Yasumoto K
Lung Cancer; 2005 May; 48(2):281-9. PubMed ID: 15829330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
